Windtree Therapeutics (WINT) Misses Q1 EPS by 12c

Windtree Therapeutics (NASDAQ: WINT) reported Q1 EPS of ($1.70), $0.12 worse than the analyst estimate of ($1.58). Revenue for the quarter came in at $75 thousand, versus $191 thousand reported last year.

For earnings history and earnings-related data on Windtree Therapeutics (WINT) click here.

You May Also Be Interested In

• Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• UBS Reiterates Buy Rating on Smurfit Westrock (SW)